Low-dose, ultra-compact X-ray technology corporations REMEDI said on the 22nd it will move to tap the market by building a local production base in India.
REMEDI is building an ultra-compact X-ray plant near New Delhi, India, with completion targeted for September. The plant site is the Kasna Industrial Area in Greater Noida, about 40 km southeast of New Delhi.
According to the company, the plant plan gained momentum with President Lee Jae-myung's recent state visit to India. REMEDI founder Lee Rena, a professor at the Ewha Womans University School of Medicine, joined as a member of the economic delegation.
REMEDI's ultra-compact X-ray device "Remex-KA6" was selected last June in the global tender for India's National Tuberculosis Elimination Program (NTEP). Since then, through April 2026, a total of 1,534 units have been supplied.
India is one of the countries with the largest tuberculosis burden in the world. The company has established a local subsidiary, "RemediX," and plans to supply devices produced at the plant to the Indian government and medical institutions.
The RemediX plant is expected to have a maximum monthly production capacity of 300 units, and will also operate a radiologic technologist training center and an after-sales service (AS) center. It plans to provide training for Indian radiologic technologists who use the devices, and offer free AS for two to three years after delivery and paid AS for three years.
According to the company, the Indian government is known to be conducting global tenders each year over the coming years to introduce about 2,000 ultra-compact X-ray devices annually. REMEDI's strategy is to secure price competitiveness and local responsiveness by building a "Make in India" production system based on technology adopted as spaceflight test equipment by the National Aeronautics and Space Administration (NASA).
Founder Professor Lee Rena said, "We have confirmed that the 1,534 devices supplied last year are being used for tuberculosis diagnosis across India," and added, "We will contribute to addressing India's national health challenges based on the local plant to be completed in the second half of this year."